Prothena (PRTA)
(Delayed Data from NSDQ)
$22.27 USD
+0.71 (3.29%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $22.33 +0.06 (0.27%) 7:28 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.27 USD
+0.71 (3.29%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $22.33 +0.06 (0.27%) 7:28 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
VRTX vs. PRTA: Which Stock Is the Better Value Option?
by Zacks Equity Research
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Prothena (PRTA) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline
by Zacks Equity Research
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Here's Why Prothena (PRTA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Prothena (PRTA) have what it takes to be a top stock pick for momentum investors? Let's find out.
INmune (INMB) Announces Positive Data for its AD Candidate
by Zacks Equity Research
INmune Bio (INMB) announces positive data for its AD candidate, XPro, from an early stage study. Shares are up in pre-market.
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
by Zacks Equity Research
AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%
Cassava (SAVA) Responds to Charges Against its Integrity in AD Study
by Zacks Equity Research
Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.
Here is Why Prothena (PRTA) is Up More Than 155% in Three Months
by Zacks Equity Research
Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.
Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena's (PRTA) earnings for the second quarter of 2021 beat estimates. Its pipeline remains in focus as the company expects to receive milestone payments from partners.
Prothena (PRTA) Q2 Earnings Top Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 1.75% and -0.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Athira (ATHA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus to be on the company's pipeline progress, mainly on its small molecule candidate ATH-1017 for Alzheimer's disease, on Athira's (ATHA) second-quarter earnings call.
Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.
Prothena (PRTA) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More
by Zacks Equity Research
The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
by Zacks Equity Research
Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.
Strength Seen in Prothena (PRTA): Can Its 7.3% Jump Turn into More Strength?
by Zacks Equity Research
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Here's Why Prothena (PRTA) Stock Is Up So Far This Month
by Zacks Equity Research
Prothena (PRTA) surges on the prospects of its Alzheimer's disease drug candidates, following Biogen???s AD drug approval.
Prothena (PRTA) Up 78.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Moves 5.9% Higher: Will This Strength Last?
by Zacks Equity Research
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.